These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 9687159)

  • 21. Serum vascular endothelial growth factor and Doppler blood flow velocities in in vitro fertilization: relevance to ovarian hyperstimulation syndrome and polycystic ovaries.
    Agrawal R; Conway G; Sladkevicius P; Tan SL; Engmann L; Payne N; Bekir J; Campbell S; Jacobs H
    Fertil Steril; 1998 Oct; 70(4):651-8. PubMed ID: 9797093
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevention of the onset of ovarian hyperstimulation syndrome (OHSS) in the rat after ovulation induction with a low molecular weight agonist of the LH receptor compared with hCG and rec-LH.
    van de Lagemaat R; Raafs BC; van Koppen C; Timmers CM; Mulders SM; Hanssen RG
    Endocrinology; 2011 Nov; 152(11):4350-7. PubMed ID: 21896671
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic importance of serial cytokine changes in ascites and pleural effusion in women with severe ovarian hyperstimulation syndrome.
    Chen CD; Wu MY; Chen HF; Chen SU; Ho HN; Yang YS
    Fertil Steril; 1999 Aug; 72(2):286-92. PubMed ID: 10438997
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Involvement of ovarian kinin-kallikrein system in the pathophysiology of ovarian hyperstimulation syndrome: studies in a rat model.
    Ujioka T; Matsuura K; Tanaka N; Okamura H
    Hum Reprod; 1998 Nov; 13(11):3009-15. PubMed ID: 9853847
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Variations in serum vascular endothelial growth factor binding profiles and the development of ovarian hyperstimulation syndrome.
    McElhinney B; Ardill J; Caldwell C; Lloyd F; McClure N
    Fertil Steril; 2002 Aug; 78(2):286-90. PubMed ID: 12137864
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of pigment epithelium-derived factor in the pathophysiology and treatment of ovarian hyperstimulation syndrome in mice.
    Chuderland D; Ben-Ami I; Kaplan-Kraicer R; Grossman H; Ron-El R; Shalgi R
    J Clin Endocrinol Metab; 2013 Feb; 98(2):E258-66. PubMed ID: 23295464
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vascular endothelial growth factor levels in serum and follicular fluid of patients undergoing in vitro fertilization.
    Lee A; Christenson LK; Stouffer RL; Burry KA; Patton PE
    Fertil Steril; 1997 Aug; 68(2):305-11. PubMed ID: 9240261
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Administration of moderate and high doses of gonadotropins to female rats increases ovarian vascular endothelial growth factor (VEGF) and VEGF receptor-2 expression that is associated to vascular hyperpermeability.
    Gómez R; Simón C; Remohí J; Pellicer A
    Biol Reprod; 2003 Jun; 68(6):2164-71. PubMed ID: 12606463
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of endothelial cells in the pathogenesis of ovarian hyperstimulation syndrome.
    Albert C; Garrido N; Mercader A; Rao CV; Remohí J; Simón C; Pellicer A
    Mol Hum Reprod; 2002 May; 8(5):409-18. PubMed ID: 11994537
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of letrozole on moderate and severe early-onset ovarian hyperstimulation syndrome in high-risk women: a prospective randomized trial.
    Mai Q; Hu X; Yang G; Luo Y; Huang K; Yuan Y; Zhou C
    Am J Obstet Gynecol; 2017 Jan; 216(1):42.e1-42.e10. PubMed ID: 27555316
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changes in vascular endothelial growth factor levels and the risk of ovarian hyperstimulation syndrome in women enrolled in an in vitro fertilization program.
    Artini PG; Fasciani A; Monti M; Luisi S; D'Ambrogio G; Genazzani AR
    Fertil Steril; 1998 Sep; 70(3):560-4. PubMed ID: 9757891
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Soluble ICAM-1 and E-selectin levels correlate with clinical and biological aspects of severe ovarian hyperstimulation syndrome.
    Abramov Y; Schenker JG; Lewin A; Kafka I; Jaffe H; Barak V
    Fertil Steril; 2001 Jul; 76(1):51-7. PubMed ID: 11438319
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New insights in mechanisms for development of ovarian hyperstimulation syndrome.
    Kasum M
    Coll Antropol; 2010 Sep; 34(3):1139-43. PubMed ID: 20977119
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model.
    Gomez R; Gonzalez-Izquierdo M; Zimmermann RC; Novella-Maestre E; Alonso-Muriel I; Sanchez-Criado J; Remohi J; Simon C; Pellicer A
    Endocrinology; 2006 Nov; 147(11):5400-11. PubMed ID: 16901966
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased risk of ovarian hyperstimulation syndrome following controlled ovarian hyperstimulation in patients with vascular endothelial growth factor +405 cc genotype.
    Hanevik HI; Hilmarsen HT; Skjelbred CF; Tanbo T; Kahn JA
    Gynecol Endocrinol; 2012 Nov; 28(11):845-9. PubMed ID: 22587628
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Administration of low-dose LH induces ovulation and prevents vascular hyperpermeability and vascular endothelial growth factor expression in superovulated rats.
    Gómez R; Lima I; Simón C; Pellicer A
    Reproduction; 2004 Apr; 127(4):483-9. PubMed ID: 15047939
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum vascular endothelial growth factor levels are poorly predictive of subsequent ovarian hyperstimulation syndrome in highly responsive women undergoing assisted conception.
    Mathur R; Hayman G; Bansal A; Jenkins J
    Fertil Steril; 2002 Dec; 78(6):1154-8. PubMed ID: 12477503
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of IL-6 trans-signaling in vascular leakage: implications for ovarian hyperstimulation syndrome in a murine model.
    Wei LH; Chou CH; Chen MW; Rose-John S; Kuo ML; Chen SU; Yang YS
    J Clin Endocrinol Metab; 2013 Mar; 98(3):E472-84. PubMed ID: 23348396
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of montelukast and cabergoline for prevention of ovarian hyperstimulation syndrome: in an experimental rat model.
    Akman L; Sahin G; Erbas O; Aktug H; Akdogan A; Goker EN; Taskiran D; Tavmergen E
    Gynecol Endocrinol; 2015 May; 31(5):369-73. PubMed ID: 25599748
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative analysis of abdominal fluid cytokine levels in ovarian hyperstimulation syndrome (OHSS).
    Farkas B; Boldizsar F; Bohonyi N; Farkas N; Marczi S; Kovacs GL; Bodis J; Koppan M
    J Ovarian Res; 2020 Mar; 13(1):25. PubMed ID: 32138790
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.